Rallybio Corporation (RLYB) Stock Score, Valuation & Financial Research

Rallybio Corporation is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for RLYB

Rallybio Corporation does not currently have a complete Wall Street Score. The stored market price is USD 16.91. These figures are a research snapshot, not a buy or sell recommendation.

What Rallybio Corporation does

Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Rallybio is a clinical-stage biotechnology company that generates revenue primarily through collaboration and license agreements related to its research and development programs. The company focuses on discovering and developing novel therapeutics for patients with severe and rare diseases, currently transitioning its strategic focus toward autoimmune disease therapeutics.

Products and services

  • The company is a clinical-stage biotechnology firm developing a portfolio of therapeutics, including RLYB116, a clinical-stage asset for autoimmune diseases, and other early-stage research programs.

Customer types

Pharmaceutical and biotechnology companies.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party service providers for clinical trial management, data collection, and the manufacturing of drug candidates for clinical use. Specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Candid Therapeutics — Rallybio entered into a merger agreement with Candid Therapeutics, a clinical-stage biotechnology company advancing a portfolio of TCE therapeutics for autoimmune diseases. Source

Business strengths to evaluate

  • Portfolio of clinical-stage therapeutic candidates Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on the success of clinical-stage product candidates Source
  • Risks associated with the pending merger with Candid Therapeutics Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

RLYB financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 16.91
Market capitalization:
89.77M (currency not supplied)
Revenue:
USD 646K
Net income:
USD 45.55M
Free cash flow:
USD -29.81M
Cash:
USD 92.85M
Total debt:
USD 176K
EPS:
USD 7.93
P/E ratio:
2.1x

What stands out

  • Reported year-over-year revenue growth is -24.7%.
  • Free cash flow is USD -29.81M, negative for the stored period.
  • The balance sheet shows USD 92.85M of cash versus USD 176K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -4615.0% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals 7051.2% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 92.67M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for RLYB

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • What is driving RLYB's revenue decline, and does the latest filing suggest the weakness is temporary or structural?
  • How long can RLYB fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is RLYB likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of RLYB's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-15.

Research-input completeness: 82% of the scoring inputs required for this public page are currently available.

How to research RLYB

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.